Anti-CD3 antibodies for type 1 diabetes: beyond expectations
- 12 August 2011
- journal article
- editorial
- Published by Elsevier BV in The Lancet
- Vol. 378 (9790), 459-460
- https://doi.org/10.1016/s0140-6736(11)60980-x
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell massDiabetologia, 2010
- No Effect of the Altered Peptide Ligand NBI-6024 on β-Cell Residual Function and Insulin Needs in New-Onset Type 1 DiabetesDiabetes Care, 2009
- GAD Treatment and Insulin Secretion in Recent-Onset Type 1 DiabetesThe New England Journal of Medicine, 2008
- CD3-specific antibodies: a portal to the treatment of autoimmunityNature Reviews Immunology, 2007
- Insulin Needs after CD3-Antibody Therapy in New-Onset Type 1 DiabetesThe New England Journal of Medicine, 2005
- Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes MellitusThe New England Journal of Medicine, 2002
- Effects of Insulin in Relatives of Patients with Type 1 Diabetes MellitusThe New England Journal of Medicine, 2002
- β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trialThe Lancet, 2001
- Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice.Proceedings of the National Academy of Sciences of the United States of America, 1994
- CYCLOSPORIN INCREASES THE RATE AND LENGTH OF REMISSIONS IN INSULIN-DEPENDENT DIABETES OF RECENT ONSET: Results of a Multicentre Double-blind TrialThe Lancet, 1986